Pneumocystis jiroveci Pneumonia in an Atypical Host

Reinbolt, Raquel E.; Alam, Shadia; Layman, Rachel M.; Shapiro, Charles L.; Lustberg, Maryam B.

doi:10.1016/j.clbc.2011.10.003

Cited by 9 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have prescribed PJP prophylaxis for patients with prolonged grade III/IV neutropenia [23], based on local practice [24] or based on the CD4 count [19].There is increasing evidence that the majority of patients will develop significant reductions in their CD4 counts post Bendamustine. Recent publications have described PJP post Bendamustine treatment [15][16][17][18]. On the basis of this series of cases and this increasing evidence of CD4 T-cell suppression, we propose that the safest practice is to ensure that all patients receive PJP prophylaxis from the beginning of treatment with Bendamustine.…”

Section: Discussionmentioning

confidence: 84%

“…Bendamustine has the potential to induce a reduction in CD4 lymphocyte counts causing a severe T-lymphocyte-mediated immunosuppression. Bendamustine is a recognized risk for opportunistic infection, including PJP [15][16][17][18]. It may result in grade 3 to 4 lymphopenia in 74% of patients and thus, a recent article has recommended bimonthly monitoring of CD4 T-helper cells with initiation of PJP prophylaxis in patients with counts less than 200/lL [19].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol

Abkur

Saeed

Ahmed

et al. 2015

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol

Abkur

Saeed

Ahmed

et al. 2015

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Patients mean age were with a range of 66.8. [16][17][18][26][27][28][29] Tables 1 and 2 provide further details about the studies.…”

Section: Resultsmentioning

confidence: 99%

Bendamustine and pneumocystis pneumonia: A systematic review

Hakamifard

Mardani

Nasiri

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background: Bendamustine, a bifunctional mechlorethamine alkylating agent, is used in the treatment of patients with hematologic malignancies. Myelosuppression and cytotoxic effect arises quite often after bendamustine treatment. To date, there have been no recommendations for routine chemoprophylaxis for Pneumocystis carinii pneumonia (PCP) in patients under treatment with this agent. The present systematic review aimed to evaluate the existing data on bendamustine effects on pneumocystis pneumonia.Method: English papers were systematically reviewed using Web of Science, Embase, Google Scholar, PubMed, and Cochrane library. There was no time constraint for the paper search. The used keywords included "Pneumonia, Pneumocystis"or "Pneumocystis Pneumonia"or "Pneumocystis jirovecii" and "Bendamustine hydrochloride or Bendamustine. "Through our search, 113 papers were found, 26 of which were chosen following a review of the titles and abstracts; ultimately, 10 were included in the research.Result: A total of 10 studies (out of 113 studies) were retrieved. The papers were classified into seven case reports, two clinical trials, and one retrospective analysis study. The case reports included 14 patients diagnosed with PCP after bendamustine administration between 2003 and 2019. The patients' mean age was with a range of 66.8. Non-Hodgkin's lymphoma (including diffuse large B-cell lymphoma and mantle cell lymphoma) (n = 9, 60%), chronic lymphocytic leukemia (n = 4, 26.6%), and breast cancer (n = 2, 13.4%) were the most prevalent types of malignancy.Bendamustine, along with rituximab, were the most commonly prescribed chemotherapy regimens during the treatments. Finally, the mortality rate among the patients whose results were reported (n = 9) was 44.44% (n = 4). Conclusion:The present review described PCP infection in patients with malignancies after the treatment with bendamustine, a chemotherapeutic agent associated with lymphopenia. Further research is required to determine the PCP risk

show abstract

“…presumably due to the effect of bevacizumab on the gastrointestinal blood supply, facilitating bowel infarction and bacterial translocation. There are anecdotal reports of Pneumocystis jiroveci pneumonia [38,39] and necrotizing fasciitis [40]. However, the contributing role of previous or concomitant cytotoxic therapies is difficult to discern.…”

Section: Available Clinical Datamentioning

confidence: 99%